Iptacopan and Danicopan for Paroxysmal Nocturnal Hemoglobinuria

Draft Questions for Deliberation and Voting: February 16, 2024 Public Meeting

These questions are intended for the deliberation of the CTAF voting body at the public meeting.

Clinical Evidence

Patient Population: Treatment-naïve PNH patients.

1. Is the currently available evidence adequate to demonstrate that the net health of iptacopan is superior to that provided by C5 inhibitor therapies (eculizumab, ravulizumab)?
   Yes  No

Patient Population: Treatment-experienced on a stable C5 Inhibitor regimen with clinically significant extravascular hemolysis EVH

2. Is the currently available evidence adequate to demonstrate that the net health benefit of switching to iptacopan is superior to that provided by continuing a C5 inhibitor?
   Yes  No

3. Is the currently available evidence adequate to demonstrate that the net health of iptacopan is superior to that provided by pegcetacoplan?
   Yes  No

4. Is the currently available evidence adequate to demonstrate that the net health benefit of danicopan added to a C5 inhibitor is superior to that provided by continuing a C5 inhibitor alone?
   Yes  No

5. Is the currently available evidence adequate to demonstrate that the net health of danicopan added to a C5 inhibitor is superior to that provided by pegcetacoplan?
Contextual Considerations and Potential Other Benefits or Disadvantages

Please vote on the following contextual considerations:

When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for PNH, on the basis of the following contextual considerations:

1= Very low priority; 2 = Low priority; 3 = Average priority; 4 = High priority; 5= Very high priority

1. Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability
2. Magnitude of the lifetime impact on individual patients of the condition being treated
3. Other (as relevant):

Please vote on the following potential other benefits or disadvantages:

Patient Population: Treatment-experienced on a stable C5 Inhibitor regimen with clinically significant extravascular hemolysis EVH

What are the relative effects of iptacopan versus C5 inhibitors on the following outcomes that inform the judgment of the overall long-term value for money of Iptacopan?

1= Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

4. Patients’ ability to achieve major life goals related to education, work, or family life
5. Caregivers’ quality of life and/or ability to achieve major life goals related to education, work, or family life
6. Patients’ ability to manage and sustain treatment given the complexity of regimen
7. Society’s goal of reducing health inequities

What are the relative effects of danicopan added to C5 inhibitors versus C5 inhibitors alone on the following outcomes that inform judgment of the overall long-term value for money of danicopan?

1= Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

8. Patients’ ability to achieve major life goals related to education, work, or family life
9. Caregivers’ quality of life and/or ability to achieve major life goals related to education, work, or family life
10. Patients’ ability to manage and sustain treatment given the complexity of regimen
11. Society’s goal of reducing health inequities

Long-Term Value for Money

**Patient Population:** Treatment-experienced on a stable C5 Inhibitor regimen with clinically significant extravascular hemolysis EVH

1. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with iptacopan versus C5 inhibitors?*
   a. High long-term value for money at [current/assumed] pricing
   b. Intermediate long-term value for money at [current/assumed] pricing
   c. Low long-term value for money at [current/assumed] pricing

*This vote will only be taken if a price becomes available for iptacopan.

2. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with danicopan added to C5 inhibitors versus C5 inhibitors alone?*
   a. High long-term value for money at [current/assumed] pricing
   b. Intermediate long-term value for money at [current/assumed] pricing
   c. Low long-term value for money at [current/assumed] pricing

*This vote will only be taken if a price becomes available for danicopan.